Special Issue "Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches 2.0"
Deadline for manuscript submissions: 31 January 2024 | Viewed by 3148
Interests: reactive oxygen species; vascular inflammation; endothelial dysfunction; biomaterials; tumor microenvironments
Special Issues, Collections and Topics in MDPI journals
2. Department of Physiology, College of Medicine, Chungnam National University, 266 Munhwa-ro, Jung-gu, Daejeon 35015, Republic of Korea
Interests: aortic inflammation; vascular inflammation; endothelial activation
The Special Issue, “Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches 2.0”, will focus on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions related to vascular inflammation.
Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. The chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment.
The pathophysiology of endothelial dysfunction (ED) is complex, and multifactorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions as well as the early detection or molecular imaging techniques for endothelial dysfunction help to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had a promising beneficial effect in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host–immune responses near tumor environments.
This Special Issue is open for a wide range of basic to preclinical research studies, or those adopting a multidisciplinary approach, and will also cover original articles and reviews on the following topics:
- Target molecules or pathophysiology
- Primary prevention of cardiovascular risk factors
- Early detection or molecular imaging techniques
- New therapeutic approaches including biomaterials development
- Drug delivery systems
- Immunology and tumor environments
Dr. Byeong Hwa Jeon
Dr. Hee Kyoung Joo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- endothelial dysfunction
- endothelial activation
- reactive oxygen species and lipid peroxidation
- adipose tissues and obesity
- vascular inflammation
- tumor microenvironment
- new biomarker or pathophysiology
- novel therapeutic approach and pharmaceuticals